Sign in

GRCE on Nasdaq

Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is an American pharmaceutical preparations company based in Princeton.1 Its shares trade on Nasdaq under the symbol GRCE.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$7.8MNet income, fiscal 20262

Compare with SIGA TECHNOLOGIES INC, Zymeworks or ZEVRA THERAPEUTICS, INC., or pick any stock.

  • TickerGRCE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersPrinceton, New Jersey1
  • Incorporated inDE3
  • Business address103 Carnegie Center, Suite 300, Princeton, Nj 085403
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-15.6%Operating margin6
-9.8%Net margin6
50920.4%Revenue growth, 20226
-9.1%Return on equity7

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development6¢$5.6M
  • Other costs94¢$93.8M
  • Income tax1¢$648.0K

Out of $100.0M in revenue.68 The company lost money this year.

Financial statements

Revenue86$100.0M in 2022+50920% since 2021
0$25.0M$50.0M$75.0M$100.0M2021: $196.0K$196.0K20212022: $100.0M$100.0M2022+50920%
Operating income91086-$15.6M in 2022−55% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$34.4M-$34.4M20192020: -$24.4M-$24.4M2020−29%2021: -$16.4M-$16.4M2021−33%2022: -$15.6M-$15.6M2022−5%
Net income91086-$9.8M in 2022−75% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$39.4M-$39.4M20192020: -$25.5M-$25.5M2020−35%2021: -$19.7M-$19.7M2021−23%2022: -$9.8M-$9.8M2022−50%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-03-312025-03-31
Research and development expenses$2.4M$9.5M
General and administrative expenses$8.7M$7.2M
Loss from operating activities-$11.1M-$16.7M
Foreign exchange loss-$1.0K-$17.0K
Change in fair value of derivative warrant liabilities$900.0K$3.2M
Interest and other income, net$685.0K$711.0K
Total other income, net$1.6M$3.9M
Loss before income tax benefit-$9.5M-$12.8M
Income tax benefit$1.7M$3.2M
Net loss-$7.8M-$9.6M
Total comprehensive loss-$7.8M-$9.6M
Basic loss per share (in Dollars per share)-$0.47-$0.79
Diluted loss per share (in Dollars per share)-$0.47-$0.79
Weighted average number of shares outstanding, basic (in Shares)16.5M shares12.1M shares
Weighted average number of shares outstanding, diluted (in Shares)16.5M shares12.1M shares

Compare Grace Therapeutics, Inc. with another company

Corporate structure

Grace Therapeutics, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Grace Therapeutics, Inc.

  • ADAR1 Capital Management, LLC Filed SCHEDULE 13G/A on Grace Therapeutics, Inc., latest Aug 14, 2026 (7 filings since Jul 10, 2024)
  • Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on Grace Therapeutics, Inc., latest Aug 14, 2026 (4 filings since May 15, 2025)
  • Opaleye Management Inc. Filed SCHEDULE 13G on Grace Therapeutics, Inc., latest Aug 7, 2026
  • Orin Hirschman Filed SCHEDULE 13G/A on Grace Therapeutics, Inc., latest Apr 27, 2026 (5 filings since Apr 9, 2024)
  • Bank of America Filed SC 13G/A on Grace Therapeutics, Inc., latest Nov 14, 2024 (2 filings since Feb 13, 2024)
  • Grace Therapeutics, Inc. Princeton, New Jersey
    • Grace Therapeutics U.S., Inc. (formerly Acasti Pharma U.S., Inc.) Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Grace Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$8.0K2 Mar 31, 2026$15.0K2 Mar 31, 2025−46.7%
Property and equipment, before depreciation$22.0K2 Mar 31, 2026$26.0K2 Mar 31, 2025−15.4%
Accumulated depreciation$14.0K2 Mar 31, 2026$9.0K2 Mar 31, 2025+55.6%
Property and equipment, net$8.0K2 Mar 31, 2026$15.0K2 Mar 31, 2025−46.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$17.0M2 Mar 31, 2026$22.1M2 Mar 31, 2025−23.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$8.1M2 Mar 31, 2026$8.1M2 Mar 31, 20250%
Intangible assets, net (excluding goodwill)$41.1M2 Mar 31, 2026$41.1M2 Mar 31, 20250%

Properties, in its own words

Our head office and operations are located at 103 Carnegie Center Suite 300 Princeton, New Jersey, 08540.

Item 2 of the 10-K filed Jun 18, 2026.5

Leadership

Who has led Grace Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Janelle D'Alvise2020–2022
  2. Prashant Kohli2023–now

President

  1. Janelle D'Alvise2020–2022
  2. Jean-Francois Boily2020

Chief operating officer

  1. Pierre Lemieux2020–2022
  2. George Kottayil2021–2022
20202025
Board members and other officers (16)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Interim Chief Financial OfficerBrian Ford named Oct 10, 202335

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Grace Therapeutics U.S., Inc. (formerly Acasti Pharma U.S., Inc.) Delaware, United States4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Acasti Pharma Inc.Sep 2, 2008 to Oct 25, 20243

Timeline

  1. Sep 18, 20268-K Shareholder vote36
  2. Aug 13, 20268-K Results of operations37
  3. Aug 6, 20268-K Entered a material agreement; Unregistered sale of shares; Other events38
  4. Jul 28, 20268-K Other events39
  5. Jun 18, 20268-K Results of operations40
  6. Jun 18, 20268-K Other events41
  7. Jun 5, 20268-K Executive or director change42
  8. Apr 27, 20268-K Other events43
  9. Apr 23, 20268-K Other events44
  10. Feb 12, 20268-K Results of operations45
  11. Jan 12, 20268-K Executive or director change46
  12. Nov 13, 20258-K Results of operations; Other events47
  13. Jul 18, 2023New chief executive Prashant Kohli becomes CEO15
  14. Apr 1, 2020New chief executive Janelle D'Alvise becomes CEO16

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.15) a share, on Nov 13, 2025.48

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results37
  2. Jun 18, 2026Reported quarterly or annual results40
  3. Feb 12, 2026Reported quarterly or annual results45
  4. Nov 13, 2025Reported quarterly or annual results47
  5. Aug 12, 2025Reported quarterly or annual results49
  6. Jun 23, 2025Reported quarterly or annual results50
  7. Feb 13, 2025Reported quarterly or annual results51
  8. Nov 13, 2024Reported quarterly or annual results52

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

229 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 68 major events, 79 insider forms, 19 large holders, 3 private raises, 37 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Oct 5, 20264 EDGAR
  3. Oct 1, 20264 EDGAR
  4. Oct 1, 20264/A EDGAR
  5. Sep 23, 20264 EDGAR
  6. Sep 21, 20264 EDGAR
  7. Sep 21, 20264 EDGAR
  8. Sep 21, 20264 EDGAR
  9. Sep 21, 20264 EDGAR
  10. Sep 18, 20268-K EDGAR
  11. Sep 10, 20264 EDGAR
  12. Sep 10, 20264 EDGAR
  13. Sep 1, 20264 EDGAR
  14. Sep 1, 20264 EDGAR
  15. Sep 1, 20264 EDGAR
  16. Sep 1, 20264 EDGAR
  17. Aug 31, 2026EFFECT EDGAR
  18. Aug 24, 2026S-3 EDGAR
  19. Aug 19, 20264 EDGAR
  20. Aug 14, 2026SCHEDULE 13G/A EDGAR

The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 23, 2026Opaleye Management Inc.10% ownerBuy5,318$2.10$11.2KForm 4
Sep 21, 2026Opaleye Management Inc.10% ownerBuy9,771$2.10$20.5KForm 4
Sep 9, 2026Opaleye Management Inc.10% ownerBuy5,836$2.09$12.2KForm 4
Sep 9, 2026Kohli PrashantChief Executive OfficerBuy100,000$2.14$214.0KForm 4
Sep 8, 2026Opaleye Management Inc.10% ownerBuy9,393$2.10$19.7KForm 4
Aug 14, 2026Opaleye Management Inc.10% ownerBuy11,608$2.09$24.3KForm 4
Sep 25, 2023Kavuru VimalDirectorBuy676,371$1.85$1.3MForm 4
Aug 31, 2023Olds DonaldDirectorBuy381$2.05$781Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Prashant KohliChief Executive Officer54$579.0K$1.3M58
2026Amresh KumarVice President, Program Management47$310.0K$465.6K58
2026Carrie D’AndreaFormer Vice President, Clinical Operations$310.0K$465.6K58
2025Prashant KohliChief Executive Officer54$500.0K$1.1M58
2025Amresh KumarVice President, Program Management47$286.0K$431.9K58
2025Carrie D’AndreaFormer Vice President, Clinical Operations$286.0K$431.9K58

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$32.7M 2020–2026
Money received by yearMoney received by year, 2020–2026: $32.7M in all. Private raises (Form D) $32.5M; PPP loans $160.0K.$0$5M$10M$15M2020 · PPP loans: $160.0K202020222023 · Private raises (Form D): $7.5M20242025 · Private raises (Form D): $15.0M2026 · Private raises (Form D): $10.0M2026
Figures by year
YearPrivate raises (Form D)PPP loansTotal
2026$10.0M–$10.0M
2025$15.0M–$15.0M
2023$7.5M–$7.5M
2020–$160.0K$160.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Aug 4, 2026Raised $10 million in a private offering of equity59 Form D: 9 investors so far Form D
  2. Feb 10, 2025Raised $15 million in a private offering of equity60 Form D: $30 million offered in all Form D
  3. Sep 25, 2023Raised $7.5 million in a private offering of equity35 Form D: $15.1 million offered in all Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA61. Matched to this company by name and state.

  1. Apr 10, 2020$160.0K PPP loan (first draw) from Valley National Bank61To GRACE THERAPEUTICS INC, East Brunswick NJ; $161.9K forgiven Jun 11, 2021

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 33. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cerity Partners LLC849,055$1.9M0.0%No change
Eversept Partners, LP772,900$1.8M0.1%+16,300
Bank Of America Corp /de/494,698$1.1M0.0%−25
Vanguard Capital Management LLC411,714$934.6K0.0%+10,058
Citadel Advisors LLC349,740$793.9K0.0%+250,998
Cantor Fitzgerald, L. P.200,000$454.0K0.0%New
Maven Securities LTD200,000$454.0K0.0%New
Birchview Capital, LP120,000$272.4K0.1%+70,000
Two Sigma Investments, LP96,890$219.9K0.0%New
Jane Street Group, LLC89,442$203.0K0.0%−77,655
XTX Topco Ltd71,668$162.7K0.0%+8,574
Susquehanna International Group, Llp49,577$112.5K0.0%New
BlackRock, Inc.37,535$85.2K0.0%New
Rangeley Capital, LLC26,000$59.0K0.1%New
Kestra Private Wealth Services, LLC23,000$52.2K0.0%+10,000
UBS Group AG16,777$38.1K0.0%−9,524
Stratos Investment Management, LLC11,158$25.3K0.0%New
Bnp Paribas Financial Markets10,500$23.8K0.0%+3,400
Scientech Research LLC10,184$23.1K0.0%New
Oppenheimer & Co Inc10,000$22.7K0.0%No change
Morgan Stanley9,448$21.4K0.0%+4,900
Vanguard Fiduciary Trust Co8,750$19.9K0.0%No change
National Bank Of Canada /fi/2,680$6.1K0.0%−36
Wells Fargo & Company/mn1,800$4.1K0.0%No change
Tower Research Capital LLC (TRC)1,652$3.8K0.0%+1,237

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Grace Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGrace Therapeutics, Inc.1
  • CIK0001444192
  • Employer ID (EIN)98-13593365
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address103 Carnegie Center, Suite 300, Princeton, NJ 085401
  • Phone609-322-16021
  • Shares outstanding21,035,930 as of Aug 11, 202613
  • Public float$35.1M as of Sep 30, 20255
  • AuditorKPMG LLP, Philadelphia, Pennsylvania PCAOB ID 185; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceSep 2, 20081
  • Filings590 in all: 6-K (230), 8-K (95), 4 (63), 3 (23), 10-Q (19), EFFECT (14), SCHEDULE 13G/A (12), CORRESP (11)1
    All 48 form types

    UPLOAD (9), 10-K (7), 20-F (6), 424B3 (6), 425 (6), DEFA14A (6), F-1/A (6), 424B5 (5), D (5), DEF 14A (5), POS AM (5), SC 13G (5), SC 13G/A (5), S-3 (4), S-8 (4), 4/A (3), F-X (3), S-8 POS (3), 10-Q/A (2), CERTNAS (2), F-3 (2), S-4 (2), S-4/A (2), SC 13D/A (2), SCHEDULE 13G (2), SUPPL (2), 10-K/A (1), 3/A (1), 40-F (1), 40FR12G (1), 40FR12G/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CB (1), F-1 (1), F-10 (1), FWP (1), PRE 14A (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Jun 18, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jul 28, 2026
    Latest 8-K (8-K) Sep 18, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareGRCENasdaq

From the cover page of the 10-K filed Jun 18, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Grace Therapeutics, Inc. names in Item 1A of its 10-K filed Jun 18, 2026: 53 risks under these headings, as written.5

  • Risks Factors Relating to our Business
  • We received a Complete Response Letter (CRL) from the FDA citing certain manufacturing deficiencies and other non-clinical issues, which may delay or prevent approval of GTx-104.
  • We may not achieve our publicly announced milestones on time, or at all.
  • We are heavily dependent on the success of our lead drug candidate, GTx-104.
  • We may not be able to maintain our operations and advance our research and development and if approved, commercialization of our GTx-104 lead drug candidate without additional funding.
  • We have no history of commercializing drugs, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations and our ability to compete.
  • We face potential product liability, and if claims are brought against us, we may incur substantial liability.
  • We rely on information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
  • Disruptions at the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent or delay new products and services from being developed, approved, or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Unfavorable global geopolitical events and economic conditions, including military conflicts and trade tensions between the U.S. and its global trading partners, including China, could adversely affect our business, financial condition or results of operations, including conduct of our clinical trials and our manufacturing activities.
The other 42 risks
  • We face risks related to the personal data we collect, process, and share.
  • We face risks related to the growth of artificial intelligence and data analytics.
  • We may not be able to maximize value from our de-prioritized drug candidates, GTx-102 and GTx-101, through either out-licensing or sale.
  • Risks Related to Development, Testing and Commercialization of Our Products
  • Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development.
  • Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and could jeopardize or delay our ability to obtain regulatory approval and commence drug product sales. We may also find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our drug candidates.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.
  • If a product candidate causes undesirable side effects, then we may be unable to receive regulatory approval or market acceptance for such product candidate.
  • Our drug development strategy relies heavily upon the 505(b)(2) regulatory pathway, which requires us to certify that we do not infringe upon third-party patents covering approved drugs. Such certifications often result in third-party claims of intellectual property infringement, the defense of which will be costly and time consuming, and an unfavorable outcome in any litigation may prevent or delay our development and commercialization efforts which would harm our business.
  • If the market opportunities for GTx-104 are smaller than we believe they are, our results of operations may be adversely affected, and our business may suffer.
  • We are subject to uncertainty relating to healthcare reform measures and reimbursement policies which, if not favorable to our drug candidates, could hinder or prevent our drug candidates’ commercial success.
  • Recent and future changes in healthcare legislation and regulations may increase the difficulty and cost to obtain marketing approval for a drug candidate, increase the costs to commercialize an approved product, and adversely affect the price set for such product.
  • If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, if we participate in these programs, we could be subject to additional rebate requirements, penalties, or other sanctions, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.
  • Our commercial success depends upon attaining significant market acceptance of our drug candidates and drug products, if approved, among physicians, nurses, pharmacists, patients, the medical community and third-party payors.
  • If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate any revenue.
  • Even if GTx-104 receives regulatory approval, we will still face regulatory difficulties.
  • Even if our drug candidates receive regulatory approval in the United States, we may never obtain regulatory approval or successfully commercialize our products outside of the United States.
  • If we obtain approval to commercialize any approved drug products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
  • We are required to obtain regulatory approval for each of our drug candidates in each jurisdiction in which we intend to market such products, and the inability to obtain such approvals would limit our ability to realize their full market potential.
  • If we are unable to differentiate our drug candidates from branded reference drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve generic products that compete with any of our drug candidates, our ability to successfully commercialize our drug candidates would be adversely affected.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • We could incur substantial costs and disruption to our business and delays in the launch of our drug candidates if our competitors and/or collaborators bring legal actions against us, which could harm our business and operating results.
  • We are subject to numerous complex regulatory requirements and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business, or subject us to civil or criminal proceedings, investigations, or penalties and may limit our ability to commercialize our products.
  • Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • Risks Relating to Our Intellectual Property
  • If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.
  • We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed alleged confidential information or trade secrets of their other clients or former employers to us.
  • Our success depends in part upon our ability to protect our intellectual property for our branded products and drug candidates.
  • If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • We may not be able to protect our intellectual property rights throughout the world.
  • If our estimates or judgments relating to our critical accounting policies for intangible assets prove to be incorrect, further impairment charges could result.
  • Risks Related to Our Dependence on Third Parties
  • If our current CMO is unable to timely resolve the deficiencies identified by the FDA in the CRL related to GTx‑104, we may be required to engage an alternative manufacturer, which could result in significant delays, increased costs, or our inability to obtain regulatory approval or commercialize GTx‑104 at all.
  • We rely on third parties to manufacture commercial and clinical supplies of our drug candidates, and we intend to rely on third parties to manufacture commercial supplies of any approved drug products. The commercialization of any of our drug products could be stopped, delayed, or made less profitable if those third parties fail to provide us with sufficient quantities of active pharmaceutical ingredients, excipients, or drug products, or fail to do so at acceptable quality levels or prices or fail to maintain or achieve satisfactory regulatory compliance.
  • We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates, and our business could be substantially harmed.
  • We may not be successful in establishing or maintaining development and commercialization collaborations, and any partner may not devote sufficient resources to the development or commercialization of our drug candidates or may otherwise fail in development or commercialization efforts, which could adversely affect our ability to develop certain of our drug candidates and our financial condition and operating results.
  • Risks Related to Tax
  • There is a significant risk that we may have been classified as a PFIC for U.S. federal income tax purposes and that such PFIC status may taint our common shares owned by U.S. Holders prior to the Domestication.
  • We may not be able to use our net operating loss carry forwards to offset future taxable income for U.S. and Canadian federal income tax purposes.
  • The IRS may not agree that we should be treated as a foreign corporation for U.S. federal tax purposes prior to the Domestication.
  • Risks Relating to Our Common Stock
  • We do not expect to pay any cash dividends for the foreseeable future.
  • The price of our common stock may be volatile.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or drug candidates.
  • We may pursue opportunities or transactions that adversely affect our business and financial condition and the public announcement of any of these or similar strategic opportunities or transactions might have a significant effect on the price of our common stock.

Legal proceedings

In the ordinary course of business, we are at times subject to various legal proceedings and disputes. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal contingencies may be adjusted to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal contingencies. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our financial position, results of operations, or cash flows. We are not currently a party to any legal proceedings that, in the opinion of management, are likely to have a material effect on our business.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
    SEC EDGAROther events
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61